aapImplantate AG (XETRA: AAQ.DE) a developer manufacturer and distributor of innovative trauma products and biomaterials announced that the European Patent Office recently granted it an important patent for its silver coating technology for medical implants.

The European patent (EP 2 437 798 B1) protects both the multifunctional antibacterial silver coating developed by the company for implants and relevant medical tools and the method as well as apparatuses for the production of such a coating. In a next step the European patent will be nationalized in many key European markets and published in different languages. After the company was granted a patent for the silver coating technology last year by the US Patent and Trademark Office (USPTO) and has this year already been granted further European patents for its LOQTEQ® and magnesium technology the patent now granted represents an important further expansion of the IP portfolio.

  The fundamental added value of the silver coating technology lies in the antibacterial property of silver. When using medical implants a biofilm can grow on the surface in which multi-resistant bacteria and germs are embedded. As a consequence infections can be caused. Silver can prevent the formation of such a biofilm leading to a potential reduction in the number of infections and reoperations. Silver coating technology can thereby make a decisive contribution to improving patient care and reducing healthcare costs. Overall the silver coating technology is not limited to use solely withaapImplantate AG’s existing portfolio; it can also be used for other orthopaedic implants and surgical instruments. The company plans the submission of the CE approval application for the first silver coated products in the second half of 2015.

About aap Implantate AG
aapis a global medical device company headquartered in Berlin Germany that develops manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company’s products which include a full line of plating systems cannulated screws and bone cement products are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company’s products are sold through its direct sales force distribution partners and license agreements with OEM partners.aap’s stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information please visit www.aap.de or download the Company’s investor relations app from the Apple’s App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks uncertainties and other factors could lead to material differences between the actual future results financial situation development or performance of the company and the estimates given here. Many factors could cause the actual results performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed inaap’s public reports. Forward-looking statements therefore speak only as of the date they are made.aapdoes not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:aapImplantate AG Fabian Franke Investor Relations Lorenzweg 5 12099 Berlin Germany
Tel.: +49 30 7501 9-134 fax: +49 30 7501 9-290 e-mail: f.franke@aap.de

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content accuracy and originality of the information contained therein.

Source: aap Implantate AG via GlobeNewswire
HUG#1912170
GlobeNewswire
http://inpublic.globenewswire.com/